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ABSTRACT
Objective To compare the safety and efficacy of overnight
closed loop delivery of insulin (artificial pancreas) with
conventional insulin pump therapy in adults with type 1
diabetes.
Design Two sequential, open label, randomised
controlled crossover, single centre studies.
Setting Clinical research facility.
Participants 24 adults (10 men, 14 women) with type 1
diabetes, aged 18-65, who had used insulin pump
therapy for at least three months: 12 were tested after
consuming a medium sized meal and the other 12 after
consuming a larger meal accompanied by alcohol.
Intervention During overnight closed loop delivery,
sensor measurements of glucose were fed into a
computer algorithm, which advised on insulin pump
infusion rates at 15 minute intervals. During control
nights, conventional insulin pump settings were applied.
One study compared closed loop delivery of insulin with
conventionalpumptherapyafteramediumsizedevening
meal (60 g of carbohydrates) at 1900, depicting the
scenario of “eating in.” The other study was carried out
afteralaterlargeeveningmeal(100gofcarbohydrates)at
2030, accompanied by white wine (0.75 g/kg ethanol)
and depicted the scenario of “eating out.”
Main outcome measures The primary outcome was the
time plasma glucose levels were in target
(3.91-8.0 mmol/L) during closed loop delivery and a
comparable control period. Secondary outcomes
included pooled data analysis and time plasma glucose
levels were below target (≤3.9 mmol/L).
Results For the eating in scenario, overnight closed loop
delivery of insulin increased the time plasma glucose
levelswereintargetbyamedian15%(interquartilerange
3-35%),P=0.002.Fortheeatingoutscenario,closedloop
deliveryincreasedthe timeplasmaglucose levelswere in
target by a median 28% (2-39%), P=0.01. Analysis of
pooled datashowedthatthe overalltimeplasmaglucose
was in target increased by a median 22% (3-37%) with
closed loop delivery (P<0.001). Closed loop delivery
reduced overnight time spent hypoglycaemic (plasma
glucose ≤3.9 mmol/L) by a median 3% (0-20%), P=0.04,
and eliminated plasma glucose concentrations below
3.0 mmol/L after midnight.
Conclusion These two small crossover trials suggest that
closed loop delivery of insulin may improve overnight
control of glucose levels and reduce the risk of nocturnal
hypoglycaemia in adults with type 1 diabetes.
Trial registration ClinicalTrials.gov NCT00910767 and
NCT00944619.
INTRODUCTION
Worldwide,type1diabetesaccountsfor5-15%
1of285
million adults with diabetes.
2 The incidence of type 1
diabetes is increasing at a rate of 3% per year, with the
highest incidence in white European populations, par-
ticularly those in northern Europe.
3 Lifelong insulin
replacement is required, but conventional regimens
for delivering insulin fail to achieve physiological glu-
cose levels resulting in an increased risk of long term
vascular complications.
4 Although educational inter-
ventions have a modest effect on outcomes these are
difficult to sustain and cannot alone facilitate optimal
glucosecontrol.
5Amajorchallengeofintensiveinsulin
therapy is the risk of hypoglycaemia,
6 with low blood
glucose levels typically lasting more than two hours a
day,
7 impeding efforts to optimise glucose control and
reducing quality of life.
6
Since early 2000, improved tools for managing type
1 diabetes have emerged. These include continuous
glucose monitors and increasingly sophisticated insu-
lin pumps. Continuous glucose monitors measure
interstitial glucose levels and, although less accurate
than conventional monitoring by finger stick testing,
they offer unprecedented insights into daily glucose
excursions
8 and their regular use improves glucose
control.
9 Insulin pumps are designed to mimic physio-
logical delivery of insulin, with pre-meal doses
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BMJ | ONLINE FIRST | bmj.com page 1 of 10determinedaccordingtothecarbohydratecontentofa
planned meal, glucose levels from finger stick testing,
and insulin sensitivity factors.
10 Basal doses are deliv-
ered at pre-programmed rates over a 24 hour period
and are intermittently adjusted according to finger
stick glucose levels. Combining continuous glucose
monitoring with pump therapy can improve the con-
trol of glucose,
11 but responding to overnight real time
data detected by sensor is impractical. More than half
ofhypoglycaemiceventsoccurovernight
12andtherisk
of hypoglycaemia increases with alcohol ingestion.
13
Thus developingmeasurestoprevent nocturnalhypo-
glycaemia is a priority.
Recent technological advances provide an opportu-
nity to combine three technologies—continuous glu-
cose monitors, insulin pumps, and a computerised
control algorithm. This forms the basis of a closed
loop system, sometimes termed an artificial pancreas,
andcharacterisedbyalgorithmdriveninsulindelivery
according to glucose levels detected by a sensor.
14-16
Research is under way to develop closed loop systems
of increasing complexity.
17 We have already shown
that overnight closed loop delivery of insulin can
improve glucosecontroland reduce the risk of noctur-
nal hypoglycaemia in children and adolescents.
18
Here, we hypothesise that these findings can be
extended to adults.
METHODS
Wecarriedouttwosequential,openlabel,randomised
controlled crossover studies comparing the overnight
closed loop delivery of insulin with conventional insu-
lin pump (continuous subcutaneous insulin infusion)
therapy(fig1).Thestudiesmimickedthetwocommon
scenariosof“eatingin”and“eatingout”inpreparation
for testing as an outpatient. In an initial study we eval-
uated closed loop delivery after a medium sized eve-
ningmeal,mimickinganeveningathomewhenclosed
loop delivery could be conveniently started with the
meal. In a second, more challenging, study mimicking
an evening out, the meal was larger, was consumed
later, and was accompanied by wine. Closed loop
delivery was started later and continued until noon
the next day.
Setting and participants
The studies were carried out at the Wellcome Trust
clinical research facility at Addenbrooke’s Hospital,
Cambridge, between February and December 2009.
Inclusion criteria were adults with type 1 diabetes
(World Health Organization criteria or confirmed
negative for C peptide), aged 18-65, and using insulin
pump therapy for at least three months. Exclusion cri-
teria were awareness of reduced hypoglycaemia and
clinically significant nephropathy, neuropathy, or
retinopathy. For the eating out scenario, we recruited
participants who could tolerate the amount of alcohol
used and excluded participants with insulin resistance
(total daily insulin dose ≥1.4 U/kg), with poor glycae-
mic control (HbA1c ≥10%), and who were pregnant or
breast feeding. Participants signed informed consent.
Figure 2 shows the flow of participants through the
study.
Eating in scenario
Of32adultsinvitedtotakepartinthestudy,13agreed
and were randomly assigned to be treated overnight
with either closed loop delivery of insulin or conven-
tional insulin pump therapy during two study nights,
separated by an interval of one to three weeks. Before
the first study visit we analysed data from continuous
glucosemonitoringforupto120hours tooptimisethe
delivery of insulin by conventional pump therapy. On
both visits participants ate an identical evening meal,
comprising 60 g of carbohydrate, at 1900, accompa-
nied by prandial insulin. We calculated the prandial
boluses according to the participants’ own insulin to
carbohydrate ratio and glucose values from finger
stick testing. During the intervention visit, closed
loop insulin delivery was applied from 1900 until
0800thenextday.Duringthecontrolvisit,participants
appliedtheirusualinsulinpumpsettingsoverthesame
timeframe.
Eating out scenario
Weapproachedafurther41adultswithtype1diabetes
and recruited 12 to a second randomised crossover
study of closed loop delivery or conventional insulin
pumptherapyafteralargeeveningmealaccompanied
by alcohol, depicting the scenario of “eating out.” On
bothvisits,onetothreeweeksapart,participantsatean
identical evening meal, comprising 100 g of carbohy-
drate, at 2030, accompanied by prandial insulin and
dry white wine (Chenin Blanc, 13% vol, Ken Forrester
Wines, South Africa). Participants drank the wine (7.2
mL/kg or 6.6 units per 70 kg participant) with or after
their meal, completing the meal by 2200. During the
interventionvisit,insulinwasdelivered byclosed loop
from 2200 until 1200 the next day. During the control
visit, participants applied their usual insulin pump set-
tings over the same timeframe.
Optimisation of continuous
subcutaneous insulin
infusion (pump therapy)
Closed loop delivery
3-5 days 1-3 weeks 1-3 weeks 1 night at
research clinic
1 night at
research clinic
Insulin pump therapy
Closed loop delivery
Insulin pump therapy
Eating in scenario
Closed loop delivery
1-3 weeks 1 night at
research clinic
1 night at
research clinic
Insulin pump therapy
Closed loop delivery
Insulin pump therapy
Eating out scenario
Visit 1 Visit 2
Fig 1 | Design of two studies comparing closed loop delivery of insulin with conventional
insulin pump therapy after two meal scenarios: eating in and eating out
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To measure subcutaneous glucose in the eating in sce-
nario we used the continuous glucose monitoring sys-
tem FreeStyle Navigator (Abbott Diabetes Care,
Alameda, CA) with a 10 hour run-in calibration per-
iod.In the eatingout scenariowe usedFreeStyleNavi-
gator with a one hour run-in calibration period. The
systems were calibrated using capillary finger stick
measurements as per manufacturer’s instructions.
The accuracy of the sensor, evaluated as the median
relative absolute difference between sensor glucose
levels and paired plasma glucose levels divided by
plasma glucose levels, was 8.0% (4.5-19.3%) in the eat-
ing in scenario and 12.0% (6.8-17.2%)in the eating out
scenario.
When participants arrived at the research clinic, we
replacedtheirinsulinpumpwithastudypump(Deltec
Cozmo;SmithsMedical,StPaul,MN).Thispumpwas
connected to the established infusion site, delivering
rapid acting insulin analogue Aspart (Novo Nordisk,
Bagsvaerd, Denmark).
Closed loop algorithm
We used an algorithm based on the model predictive
control approach.
1819 Every 15 minutes a research
nurse initiated a control cycle; the nurse inputted the
sensor glucose value into the computer based
algorithm and adjusted the insulin pump according to
thebasalinfusionratecalculatedbythealgorithm.The
calculations utilised a compartment model of glucose
kinetics,
20 describing the effect of rapid acting insulin
and the carbohydrate content of meals on glucose
excursions detected by the sensor. The algorithm was
initialisedusingparticipant’sweight,totaldailyinsulin
dose,andbasalinsulinrequirements.Additionally,the
algorithm was provided with glucose levels measured
by the sensor during a 30 minute period preceding the
start of closed loop delivery, the carbohydrate content
of the evening meal, and the prandial insulin bolus.
The algorithm adapted itself to participants by updat-
ing two model variables: an endogenous glucose flux
correcting for errors in model based predictions, and
carbohydrate bioavailability. Several competing mod-
els differing in the absorption of subcutaneous insulin
and oral carbohydrates ran in parallel.
21 A combined
modelforecastedplasmaglucoseexcursionsovera2.5
hour prediction horizon. The algorithm aimed to
achieve glucose levels between 5.8 and 7.3 mmol/L
and adjusted the actual level depending on fasting ver-
sus postprandial status, preceding glucose levels, and
the accuracy of predictions made by the compartment
model. Safety rules limited maximum insulin infusion
and suspended insulin delivery when the sensor mea-
sured glucose at or below 4.3 mmol/L or when the
sensor detected that glucose was decreasing rapidly.
We used algorithm version 0.02.04 to 0.02.18.
Plasma glucose and plasma insulin sampling
We collected venous samples for glucose determina-
tion every 15 minutes and for insulin assay every
30 minutes.In the eating in scenario we collected sam-
ples between 1830 and 0800 and in the eating out sce-
nario between 1930 and 1200. These data were not
used to alter insulin infusion rates during the visits for
closed loop delivery or control. In the eating out sce-
nario we collected additional samples for determina-
tion of ethanol at 2030, 2200, and midnight and then
three hourly until 1200 the next day.
Assays
We used YSI2300 STAT Plus Analyser (YSI, Lynch-
ford House, Farnborough, UK) to determine plasma
glucose levels, and an immunochemiluminometric
assay (Invitron; Monmouth, UK) with an intra-assay
coefficient of variation of 4.7% and an interassay coef-
ficient of variation of 7.2% to 8.1% for plasma insulin
assay. We determined plasma ethanol levels using the
Completed study and analysed (n=12) Completed study and analysed (n=12)
Recruited participants (n=25)
Dropout due to logistical
problems (n=1)
Participants randomly
assigned to insulin
pump therapy (n=6)
Participants randomly
assigned to closed
loop delivery (n=7)
Participants randomly
assigned to insulin
pump therapy (n=6)
Participants randomly
assigned to closed
loop delivery (n=6)
Participants
assigned to closed
loop delivery (n=5)
Participants
assigned to insulin
pump therapy (n=7)
Participants
assigned to closed
loop delivery (n=6)
Participants
assigned to insulin
pump therapy (n=6)
Visit 1 Visit 2
Eating in scenario Eating out scenario
Fig 2 | Flow of participants through study comparing closed loop delivery of insulin with
conventional insulin pump therapy after a medium sized evening meal (eating in scenario), and
study comparing closed loop delivery with insulin pump therapy after a large evening meal
accompanied by alcohol (eating out scenario)
Table 1 |Baseline characteristics of participants completing two meal scenarios to compare closed loop delivery of insulin with conventional insulin pump
therapy. Values are means (standard deviations) unless stated otherwise
Meal scenarios
No of
participants
No of men/No
of women
Age
(years)
Body mass
index
HbA
1c
(%)
Duration of diabetes
(years)
Duration of pump use
(years)
Total daily insulin dose
(U/kg/day)
Eating in* 12 5/7 37.7 (8.5) 24.6 (2.6) 7.8 (0.5) 21.5 (10.0) 2.9 (3.5) 0.80 (0.20)
Eating out† 12 5/7 37.3 (9.9) 26.8 (4.2) 7.8 (0.7) 19.7 (9.7) 1.9 (2.6) 0.66 (0.13)
Both scenarios 24 10/14 37.5 (9.1) 25.7 (4.2) 7.8 (0.6) 20.6 (9.7) 2.4 (3.0) 0.73 (0.17)
*Medium sized evening meal (60 g carbohydrate).
†Large evening meal (100 g carbohydrate) accompanied by alcohol.
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with an intra-assay coefficient of variation of 2.4% and
an interassay coefficient of variation of 5.71%.
Sample size
Based on previous studies
18 we anticipated that over-
nightclosedloopdeliverywouldincreasethetimethat
plasma glucose concentrations were between 3.91 and
8.00mmol/Lbyamean37%(SD40%).Wecalculated
that 12 participants would provide 80% power at the
5% level of significance to detect this difference
betweenconventionalandclosedloopinsulindelivery
systems.
Randomisation and masking
Foreachstudyweplacedacomputergeneratedalloca-
tion sequence with permuted block four randomisa-
tion in sealed envelopes. Participants were
randomised on recruitment. During the eating in sce-
nario,investigatorswereblindedtotheplasmaglucose
data. For safety reasons,during the eating out scenario
investigators had access to plasma glucose levels. Dur-
ing both studies, participants did not have access to
data on plasma or sensor glucose levels.
Statistical analysis
Senior investigators and study statisticians agreed on
the analysis plan in advance. The primary outcome
was the percentage time plasma glucose concentra-
tions were in the target range (3.91-8.00 mmol/L)
between 1900 and 0800 in the eating in scenario and
between 2200 and 1200 in the eating out scenario. Sec-
ondaryoutcomeswerethemeanglucoseconcentration,
time when glucose concentration was 3.9 mmol/L or
less(hypoglycaemia),time when glucoseconcentration
was greater than 8.0 mmol/L (hyperglycaemia), mean
rate of insulin infusion, and mean plasma insulin
concentration for both separate and pooled study data.
Weestimatedglycaemicvariabilitybymeanamplitude
ofglycaemicexcursions
22andstandarddeviationofglu-
cose concentration. Secondary outcomes were calcu-
lated for both plasma and sensor glucose levels as well
as for the period from midnight to end of closed loop
control.
We used the low blood glucose index to assess the
durationandextentofhypoglycaemia,calculatedasan
average of transformed glucose measurements pro-
gressively increasing at low glucose levels.
23 Safety
assessments examined plasma glucose levels below
3 mmol/L and above 16.7 mmol/L.
Foreachoutcomewe fitarepeatedmeasuresregres-
sion model based on the ranked normal transforma-
tion (except for the mean glucose concentration
which was not transformed because it already had an
approximate normal distribution) to compare the two
treatments adjusting for plasma glucose level at the
start of closed loop delivery. We carried out analyses
using SAS software, version 9.1 and SPSS, version 15.
Kernel density of plasma glucose was estimated using
the package “np” (non-parametric kernel smoothing
methods for mixed data types), version 0.40-1, adopt-
ing a bandwidth of 0.25 mmol/L and implemented in
the R, version 2.11.1 (R Foundation for Statistical
Computing).
RESULTS
Eating in scenario
One participant who was unable to attend the second
visit for logistical reasons withdrew and was excluded
from the analysis. Table 1 shows the baseline charac-
teristics of the remaining participants. Figure 3 shows
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Fig 3 | Profiles (medians and interquartile ranges) of plasma glucose and insulin concentrations
and insulin infusion in eating in scenario (12 participants). Outlying squares represent
hypoglycaemic events (glucose level <3.0 mmol/L)
Table 2 |Time plasma glucose level in target during closed loop delivery of insulin and
conventional insulin pump therapy in two meal scenarios. Values are medians (interquartile
ranges) unless stated otherwise
Meal scenarios
Time (%) when plasma glucose in target range* Paired difference†
(%) (n=12) P value Closed loop (n=12) Insulin pump (n=12)
Eating in‡ 80 (60 to 94) 51 (39 to 75) 15 (3 to 35) 0.002
Eating out§ 70 (60 to 86) 47 (28 to 66) 28 (2 to 39) 0.01
*Target range 3.91-8.0 mmol/L.
†Closed loop minus insulin pump. Positive value indicates measurement was higher on night of closed loop
delivery compared with night of pump therapy.
‡Closed loop delivery from 1900 to 0800.
§Closed loop delivery from 2200 to 1200.
RESEARCH
page 4 of 10 BMJ | ONLINE FIRST | bmj.comthe profiles of plasma glucose and plasma insulin con-
centrations and insulin infusion. The time spent with
plasmaglucoselevelsintargetrangeincreasedby15%
(3-35%)duringclosedloopdelivery(P=0.002;table 2).
Closed loop delivery decreased glucose variability
overnight (reduced standard deviation of plasma glu-
cose 1.2 v 1.8 mmol/L, P=0.02; table 3). It also
decreased the time spent hyperglycaemic (11% v
27%, P=0.01) and the low blood glucose index (0.8 v
1.5,P=0.03).Insulininfusionwasmorevariableduring
closed loop delivery, but the average insulin infusion
rate and plasma insulin concentrations were similar
during closed loop delivery and control visits (fig 3).
From midnight, when participants were sleeping,
closed loop delivery achieved near normal glycaemia,
with plasma glucose levels in target range for 92% of
the time (interquartile range 70-100%) compared with
45% (27-80%) on control nights, with a difference of
29%(6-46%)favouringclosedloopdelivery(P=0.003).
The eating out scenario
Table 1 shows the characteristics of the participants.
Useofalcoholduringclosedloopdeliveryandcontrol
visits was comparable (peak ethanol concentration
15.0 (13.7-18.0) mmol/L v 16.5 (14.2-20.8) mmol/L)
as was time to peak ethanol concentration (150 (90-
210) minutes v 90 (90-90) minutes) and area under the
concentration curve per 15.5 hours (4151 (3375-4779)
mmol/L v 4766 (3020-5374) mmol/L). Alcohol inges-
tiondidnotaffecttheperformanceofclosedloopdeliv-
ery, which increased the time plasma glucose was in
target range by 22% (3-37%), P=0.01.
Table 4 shows secondary outcomes, all favouring
closedloop deliveryofinsulin.Asforthe eatingin sce-
nario, the average overnight infusion of insulin and
plasmainsulinconcentrationduringclosedloopdeliv-
ery and pump therapy were comparable. The profiles
for glucose and insulin levels showed lower variability
of plasma glucose during closed loop delivery from
0200 onwards (fig 4).
Hypoglycaemic and hyperglycaemic events
During closed loop delivery, four hypoglycaemic
events (glucose level <3.0 mmol/L) were observed,
two in the eating in scenario and two in the eating out
scenario. All occurred before midnight and all were
associated with symptoms. Three were attributable to
the preceding prandial insulin dose and could not be
Table 3 |Secondary comparisons in eating in scenario based on plasma glucose concentrations. Values are medians
(interquartile ranges) unless stated otherwise
Period and outcome
Insulin delivery system
Paired difference*
(n=12) P value
Closed loop
(n=12)
Insulin pump
(n=12)
From start of closed loop delivery† †
Mean(SD)plasmaglucoselevelatstartofclosedloopdelivery
(mmol/L)
6.1 (1.5) 5.9 (2.7) 0.2 (3.8) —
Mean (SD) overnight plasma glucose level (mmol/L) 6.7 (1.4) 6.7 (1.5) 0.0 (1.0) 0.98
SD of overnight plasma glucose level (mmol/L) 1.2 (0.9 to 1.4) 1.8 (1.3 to 2.3) −0.5 (−1.0 to −0.1) 0.02
Mean amplitude of glucose excursions (mmol/L) 2.6 (2.0 to 3.7) 4.6 (3.4 to 5.4) −1.7 (−3.7 to −0.4) 0.03
Time spent at plasma glucose level (%):
≤3.5 mmol/L 0 (0 to 3) 1 (0 to 14) −1( −11 to 0) 0.09
≤3.90 mmol/L 1 (0 to 9) 3 (0 to 25) −3( −18 to 0) 0.19
>8.0 mmol/L 11 (0 to 38) 27 (11 to 50) −8( −15 to 1) 0.01
Low blood glucose index 0.8 (0.0 to 2.2) 1.5 (0.5 to 4.4) −0.8 (−2.8 to −0.2) 0.03
Insulin infusion (U/h) 0.7 (0.5 to 0.8) 0.8 (0.6 to 0.9) 0.0 (−0.2 to 0.1) 0.41
Insulin concentration (pmol/L) 76 (52 to 104) 96 (65 to 124) −4( −15 to 1) 0.22
After midnight‡ ‡
Mean (SD) overnight plasma glucose level (mmol/L) 6.7 (1.3) 6.8 (2.3) −0.1 (1.6) 0.91
SD overnight plasma glucose level (mmol/L) 0.8 (0.6 to 1.1) 0.9 (0.6 to 1.9) 0.0 (−1.0 to 0.3) 0.55
Mean amplitude of glucose excursions (mmol/L) 2.6 (1.7 to 3.0) 2.7 (1.4 to 4.2) 0.2 (−2.2 to 0.6) 0.59
Time plasma glucose level spent in target (%)§ 92 (70 to 100) 45 (27 to 80) 29 (6 to 46) 0.003
Time spent at plasma glucose level (%):
≤3.5 mmol/L 0 (0 to 0) 0 (0 to 11) 0 (−11 to 0) 0.03
≤3.90 mmol/L 0 (0 to 0) 0 (0 to 23) 0 (−23 to 0) 0.15
>8.0 mmol/L 1.6 (0 to 29) 24 (0 to 70) −8( −29 to 0) 0.01
Low blood glucose index 0.1 (0.0 to 0.8) 0.7 (0.1 to 4.9) −0.4 (−4.3 to −0.0) 0.02
Insulin infusion (U/h) 0.8 (0.6 to 0.9) 0.8 (0.6 to 0.9) 0.1 (−0.2 to 0.2) 0.89
Insulin concentration (pmol/L) 51 (31 to 81) 70 (50 to 82) −7( −20 to 10) 0.23
*Closed loop minus insulin pump. Positive value indicates measurement was higher on night of closed loop delivery compared with night of insulin
pump therapy.
†From start of closed loop control at 1900 to 0800 in eating in scenario.
‡From midnight to 0800 in eating in scenario.
§Target range 3.91-8.0 mmol/L.
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atelyafterthestartofclosedloop.Threeepisodeswere
treated with 15-36 g of oral carbohydrates in drink
(Lucozade; GlaxoSmithKline, Brentford, UK) and
the fourth lasted 30 minutes with spontaneous recov-
ery. When data collected after midnight, while partici-
pants slept, were combined (968 readings), no plasma
glucosemeasurementwasbelow3.0mmol/L,7(<1%)
were below 3.3 mmol/L, and 8 (<1%) were below
3.5 mmol/L.
During insulin pump therapy, one hypoglycaemic
episode with glucose level below 2.0 mmol/L occurred
at 0215 in the eating out scenario. The episode was not
associated with symptoms but was treated with 30 g of
oralcarbohydratesindrink.Thatstudynightwastermi-
nated, as per protocol. Another six hypoglycaemic
events with glucoselevelsbelow 3.0 mmol/Loccurred,
five in the eating in scenario and one in the eating out
scenario. Two were associated with symptoms and
together with another event at 3.0 mmol/L, which also
occurred before 0100, were treated with 15-18 g oral
carbohydrates in drink. The remaining four events
were not associated with symptoms; all but one event
occurred after 0100 and were not treated. When data
collectedaftermidnightwere combined(939readings),
2(<1%)plasmaglucosevalueswerebelow2.5mmol/L,
10 (1%) were below 3.0 mmol/L, 41 (4%) were below
3.3 mmol/L, and 72 (8%) were below 3.5 mmol/L.
No hyperglycaemic events (glucose concentrations
above 16.7 mmol/l) occurred during either treatment.
Aftermidnight,allplasmaglucoseconcentrationsdur-
ing closed loop delivery were below 12 mmol/L and
during pump therapy were below 13.5 mmol/L.
Pooled analysis of studies
When data from both studies were combined, closed
loop delivery increased the time when plasma glucose
was in target by 22% (3-37%), P<0.001. Closed loop
delivery reduced overnight time spent below target
by 3% (0-20%), P=0.04. Closed loop delivery signifi-
cantly reduced the variability in plasma glucose levels
and reduced time when the levels were above target
(table 5). Closed loop delivery consistently outper-
formed conventional insulin pump therapy at both
high and low glucose values (fig 5).
DISCUSSION
Overnight closed loop delivery of insulin improved
glucose control and reduced exposure to low plasma
glucose levels in adults with type 1 diabetes, even after
Table 4 |Secondary comparisons in eating out scenario based on plasma glucose concentrations. Data are medians
(interquartile ranges) unless stated otherwise
Period and outcome
Insulin delivery system
Paired difference*
(n=12) P value
Closed loop
(n=12)
Insulin pump
(n=12)
From start of closed loop delivery† †
Mean (SD) plasma glucose level at start (mmol/L) 8.1 (3.5) 9.5 (3.8) −1.4 (4.5) —
Mean (SD) overnight plasma glucose level (mmol/L) 6.8 (0.8) 6.9 (1.6) −0.1 (1.3) 0.68
SD of overnight plasma glucose level (mmol/L) 1.7 (1.3 to 2.0) 2.2 (1.8 to 2.8) −0.5 (−0.9 to 0.1) 0.06
Mean amplitude of glucose excursions (mmol/L) 3.8 (3.5 to 5.4) 6.6 (4.3 to 8.8) −1.2 (−5.2 to 0.0) 0.16
Time spent at plasma glucose level (%):
≤3.5 mmol/L 1 (0 to 6) 8 (0 to 18) −3( −14 to 2) 0.13
≤3.90 mmol/L 4 (0 to 10) 14 (0 to 26) −5( −22 to 4) 0.21
>8.0 mmol/L 23 (10 to 36) 31 (12 to 57) −21 (−31 to 6) 0.12
Low blood glucose index 1.2 (0.7 to 1.8) 2.8 (0.6 to 4.7) −0.9 (−3.2 to 0.5) 0.37
Insulin infusion (U/h) 0.8 (0.6 to 1.1) 0.9 (0.6 to 1.1) 0.1 (−0.1 to 0.2) 0.65
Insulin concentration (pmol/L) 139 (102 to 174) 129 (105 to 208) −8( −17 to 7) 0.59
After midnight‡ ‡
Mean (SD) overnight plasma glucose level (mmol/L) 6.7 (0.6) 6.8 (2.1) −0.1 (1.8) 0.61
SD of overnight plasma glucose level (mmol/L) 1.5 (1.3 to 1.9) 1.8 (1.0 to 2.3) −0.3 (−0.7 to 0.6) 0.46
Mean amplitude of glucose excursions (mmol/L) 3.8 (2.9 to 5.1) 4.3 (3.5 to 7.2) −0.4 (−3.5 to 1.2) 0.34
Time plasma glucose level spent in target (%) 74 (63 to 87) 53 (27 to 67) 33 (4 to 41) 0.005
Time spent at plasma glucose level (%):
≤3.5 mmol/L 0 (0 to 2) 5 (0 to 19) −1( −19 to 0) 0.12
≤3.90 mmol/L 0 (0 to 4) 9 (0 to 27) −1( −26 to 0) 0.25
>8.0 mmol/L 20 (9 to 35) 31 (0 to 64) −16 (−41 to 12) 0.37
Low blood glucose index 0.6 (0.5 to 1.3) 2.0 (0.3 to 4.9) −0.7 (−4.0 to 0.1) 0.55
Insulin infusion (U/h) 0.9 (0.7 to 1.1) 0.9 (0.6 to 1.1) 0.1 (0.0 to 0.3) 0.36
Insulin concentration (pmol/L) 118 (77 to 135) 100 (75 to 149) 3 (−13 to 19) 0.80
*Closed loop delivery minus pump therapy. Positive value indicates measurement was higher on night of closed loop delivery compared with night of
pump therapy.
†From start of closed loop control at 2200 to 1200 in eating out scenario.
‡From midnight to 1200 in eating out scenario.
§Target range 3.91-8.0 mmol/L.
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The time plasma glucose levels were at or below
3.9 mmol/L was halved, and after midnight we did
not observe plasma glucose values below 3.0 mmol/L.
The average dose of insulin delivered during closed
loop and conventional pump therapy was comparable,
illustrating the key role of glucose responsive insulin
deliverytoachieve target glucose levels. The large eve-
ning meal and alcohol intake provided a greater chal-
lenge to closed loop delivery than did a medium sized
evening meal, reflected by a slightly reduced but still
superior performance over insulin pump therapy.
Strengths and limitations of the study
An important feature of our closed loop algorithm is
avoidanceofhypoglycaemia,whichifreplicatedinthe
home setting would revolutionise patient safety. The
algorithm suspends insulin delivery when the sensor
detects a low or rapid fall in glucose levels and does
so without increased risk of hyperglycaemia.
24 Initia-
tionofthealgorithmisstraightforward,requiringusers
toinputtheirweight,totaldailyinsulindose,and basal
infusion rates. The system updates advice on insulin
dose using a robust, computationally efficient
approach suitable for use with insulin pumps and
hand held devices to facilitate practical use. It can dis-
criminate between slowly or rapidly absorbed meals,
thuscopingwithconsiderablevariabilityingutabsorp-
tion. Similarly, variability in insulin absorption is
assessedthroughmodelbasedanalysisofinsulindeliv-
ery and the effects on sensor glucose levels. These
adaptive capabilities set our algorithm apart from
most existing non-adaptive approaches.
25-27
Additional strengths of our study are that we used
the closed loop system in circumstances near to those
inreallife,withoutartificiallyimprovingperformance.
Firstly, we used a commercially available continuous
glucose monitor calibrated according to manufac-
turer’s instructions. Secondly, only one sensor was
inserted and it was not recalibrated in the event of sub-
optimal accuracy. Thirdly, the advice of the algorithm
was always adhered to. Our studies assessed closed
loop delivery of insulin in preparation for home test-
ing, when recalibration of a sensor is impractical (par-
ticularly overnight), and multiple sensors, although
improving accuracy, are inconvenient and likely to
affect users’ satisfaction.
Limitationsarethatparticipantswerecompliantand
predominantly of white ethnicity, hence applicability
tolesscompliantpeopleandthosewithpoorglycaemic
control is unknown. Also, we did not adjust for multi-
ple statistical comparisons in secondary outcomes;
hence these should be considered hypothesis generat-
ing rather than conclusive. Another limitation is that
the research nurse manually entered sensor glucose
values into the algorithm and manually adjusted the
insulin pump. Presumably the lack of automation did
nottoaffecttheperformanceofthe closedloopsystem
but will need to be dealt with before proceeding to
home testing. The evening meals were standardised
for carbohydrate but not for fat or protein content,
but given that identical meals were eaten on both
study occasions, this should not affect the results.
Comparison with other studies
Our earlier studies described the benefits of overnight
closed loop delivery of insulin in children and adoles-
cents after a large evening meal and moderate
exercise.
18 They documented a 20% increase in the
time that plasma glucose levels were in target and a
halving of the time spent hypoglycaemic with the
same closed loop algorithm.
18 The present study pro-
videsfurtherevidencethatovernightclosedloopdeliv-
ery can operate safely, effectively, and consistently
across different age groups, insulin sensitivities, and
lifestyle conditions, including large evening meals,
evening exercise, and alcohol intake.
Aftertheeveningintakeofalcohol,weexpectedlate
morning hypoglycaemia during conventional insulin
pump therapy, as observed in a previous study
28 at
similar ethanol concentrations. This may be attributed
todifferencesinprotocolasweoptedtoomitbreakfast
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lunchtime (not uncommon in young adults). Another
difference wasthat in ourstudy alcoholwas consumed
within two hours of the evening meal compared with
three hours later in the other study. Nevertheless, our
data confirm that alcohol ingestion is unlikely to inter-
fere with closed loop delivery of insulin.
Recently, several studies of overnight and day and
night closed loop delivery have been reported.
25-2729
None had a randomised study design and most evalu-
ated algorithm performance rather than its clinical
application. Further studies are required to quantify
the barriers and benefits of novel approaches, includ-
ing fully automated insulin delivery, use of
glucagon,
2729 and intraperitoneal insulin delivery.
30
Testing in the home setting and over several nights is
now needed to determine the effectiveness on longer
term glycaemic control.
Conclusions and policy implications
Introduction of closed loop systems for the delivery of
insulin into clinical practice and clinical decision
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Table 5 |Comparisons between closed loop delivery of insulin and conventional insulin pump therapy based on plasma
glucose concentrations after pooling results for two meal scenarios: eating in and eating out. Data are medians
(interquartile ranges) unless stated otherwise
Period and outcome
Insulin delivery system
Paired difference*
(n=24) P value
Closed loop
(n=24)
Insulin pump
(n=24)
From start of closed loop delivery† †
Mean (SD) plasma glucose level at start (mmol/L) 7.1 (2.8) 7.7 (3.7) −0.6 (4.2) —
Mean (SD) overnight plasma glucose level (mmol/L) 6.7 (1.1) 6.8 (1.5) −0.1 (1.1) 0.84
SD of overnight plasma glucose level (mmol/L) 1.4 (1.1 to 1.8) 2.0 (1.6 to 2.7) −0.5 (−1.0 to −0.1) 0.001
Mean amplitude of glucose excursions (mmol/l) 3.6 (2.4 to 4.0) 5.0 (3.6 to 8.4) −1.5 (−4.0 to 0.0) 0.003
Time plasma glucose level spent in target (%) 76 (60 to 88) 50 (32 to 70) 22 (3 to 37) <0.001
Time spent at plasma glucose level (%):
≤3.5 mmol/L 0 (0 to 4) 4 (0 to 17) −1( −12 to 0) 0.02
≤3.90 mmol/L 3 (0 to 9) 7 (0 to 25) −3( −20 to 0) 0.04
>8.0 mmol/L 18 (2 to 36) 30 (12 to 54) −11 (−30 to 1) 0.006
Low blood glucose index 1.0 (0.5 to 2.0) 1.9 (0.5 to 4.5) −0.9 (−3.0 to 0.1) 0.01
Insulin infusion (U/h) 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.0) 0.0 (−0.1 to 0.2) 0.83
Insulin concentration (pmol/L) 104 (68 to 148) 109 (91 to 159) −7( −16 to 2) 0.14
After midnight‡ ‡
Overnight plasma glucose level (mmol/L) 6.7 (1.0) 6.8 (2.2) −0.1 (1.7) 0.66
SD of overnight plasma glucose level (mmol/L) 1.2 (0.8 to 1.5) 1.5 (0.7 to 2.0) −0.2 (−0.8 to 0.4) 0.28
Mean amplitude of glucose excursions (mmol/L) 2.9 (2.3 to 4.1) 3.9 (1.8 to 5.6) −0.1 (−2.5 to 0.9) 0.27
Time plasma glucose spent in target (%)§ 81 (63 to 99) 51 (27 to 67) 32 (6 to 43) <0.001
Time spent at plasma glucose level (%):
≤3.5 mmol/L 0 (0 to 0) 0 (0 to 17) 0 (−17 to 0) 0.007
≤3.90 mmol/L 0 (0 to 3) 0 (0 to 27) 0 (−26 to 0) 0.04
>8.0 mmol/L 13 (0 to 34) 31 (0 to 67) −8( −37 to 1) 0.09
Low blood glucose index 0.5 (0.1 to 1.1) 1.2 (0.2 to 4.9) −0.6 (−4.0 to −0.0) 0.02
Insulin infusion (U/h) 0.9 (0.6 to 1.0) 0.9 (0.6 to 1.0) 0.1 (−0.1 to 0.2) 0.46
Insulin concentration (pmol/L) 81 (48 to 127) 78 (69 to 124) 1 (−16 to 13) 0.20
*Closed loop delivery minus insulin pump therapy. Positive value indicates measurement was higher on night of closed loop delivery compared with
night of insulin pump therapy.
†From start of closed loop control: 1900 to 0800 in eating in scenario and 2200 to 1200 in eating out scenario.
‡From midnight to 0800 in eating in scenario and from midnight to 1200 in eating out scenario.
§Target range 3.91-8.0 mmol/L.
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blems, such as reduction in the duration or severity of
hypoglycaemia. As continuous glucose monitors and
controlalgorithmsareperfected,devicesminiaturised,
and performance limiting aspects identified, it is anti-
cipatedthatearlyclosedloopapproachessuchasover-
night closed loop delivery will be followed by more
advanced solutions for control of glucose during both
thedayandatnight.Closedloopsystemsmayserveas
a bridge until type 1 diabetes is cured by, for example,
stem cell therapy or islet transplantation.
In conclusion, closed loop delivery of insulin can
significantly improve the control of glucose levels
overnightandreducetheriskofnocturnalhypoglycae-
miainadultswithtype1diabetes.Theclosedloopsys-
tem has the potential to improve safety and efficacy of
insulin delivery and may in future allow more flexible
lifestylesinconjunctionwithimprovedglycaemiccon-
trol for people with type 1 diabetes.
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